食管癌组织KAI1/CD82、MRP1/CD9的表达及其临床意义  

Expressions and clinical significance of KAI1/CD82 and MRP1/CD9 in esophageal cancer

作　　者：季润元[1] 束晓明[2] 张徐宁[1] 李雪甫[1] 沈阳[3] 王成海[4] 冯振卿[5] 

机构地区：[1]淮阴卫生高等职业技术学校淮安市消化道肿瘤重点实验室,223300 [2]淮安市第一人民医院妇产科 [3]淮安市第二人民医院病理科 [4]扬州大学医学院病理教研室 [5]南京医科大学病理学系

出　　处：《江苏医药》2010年第13期1498-1501,共4页Jiangsu Medical Journal

基　　金：江苏省卫生厅医学科技发展基金(J200611)

摘　　要：目的探讨食管癌组织中KAI1/CD82、MRP1/CD9的表达及其临床意义。方法应用免疫组化SABC法检测54例食管癌组织中KAI1/CD82、MRP1/CD9的表达,并进行分析比较。结果食管癌组织KAI1/CD82的阳性表达率为61.5%(32/52)、MRP1/CD9的阳性表达率为57.4%(31/54)。两者的表达与淋巴结转移、肿瘤的分级、术后存活时间显著相关(P<0.05)。结论 KAI1/CD82、MRP1/CD9可作为食管癌的预后指标。Objective To investigate the correlation between the expressions of KAI1/CD82 and MRP1/CD9 in esophageal cancer and their pathologic clinical significance.Methods The expressions of KAI1/CD82 and MRP1/CD9 were detected by SABC immunohistochemical method in 54 cases with esophageal cancer.Results The rate of positive expression of KAI1/CD82 was 61.5%（32/52） and that of MRP1/CD9 was 57.4%（31/54） in esophageal cancer tissue.The expressions of KAI1/CD82 and MRP1/CD9 were significantly correlated with lymph node metastasis stage of tumor and survival time after surgery（P0.05）.Conclusion KAI1/CD82 and MRP1/CD9 can be taken as the markers for predicting the prognosis of esophageal cancer.

关 键 词：KAI1/CD82 MRP1/CD9 食管癌 

分 类 号：R735[医药卫生—肿瘤]